Lithium administration (LiC1, 10 mmol/kg, SC on day 1, followed by 3 mmol/kg twice daily subsequently) for 14 days to mice produced attenuation of the hypothermic response to injection of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 0.5 mg/kg SC). Head twitch responses to the 5-HT-receptor agonist 5-methoxy-N,N-dimethyltryptamine (2.5 mg/kg IP) and to precursor loading with carbidopa (25 mg/kg, IP) and 5-hydroxytryptophan (100 mg/kg IP) were similarly attenuated. By contrast with this reduction of 5-hydroxytryptamine (5-HT) function mediated by the 5-HTIA and 5-HT2 receptor sub-types, repeated lithium administration had no effect on the motor response to a putative 5-HTIB receptor agonist 5-methoxy-3(1,2,3,6-tetrahydropyridin-4-yl)lH indole (RU 24969, 3 mg/kg IP). Alpha2 adrenoceptor function, assessed by the sedation response to elonidine (0.25 mg/kg, IP), was also attenuated by repeated lithium administration. It is proposed that these actions may explain the emergence of lithium as an adjunct to the treatment of refractory depressive illness.
1 The effects of calcium antagonists on behaviour mediated by 5-hydroxytryptamine (5-HT) have been studied in rats and mice together with an investigation of the effects of these drugs on 5-HT synthesis in rat brain and endogenous 5-HT release from brain slices. 2 Administration of felodipine (35mg kg-i.p.) to rats pretreated with tranylcypromine (20mg kg-1, i.p.) resulted in the animals displaying the complete 5-HT-mediated behavioural syndrome (including head weaving, reciprocal forepaw treading and hind limb abduction) 75 min later. No evidence was obtained for the rate of 5-HT synthesis in brain regions differing between control and felodipine-treated rats. 3 Pretreatment with felodipine (10 or 35mg kg-1) enhanced the 5-HT-mediated behavioural syndrome induced by injection of tranylcypromine and L-tryptophan. The rate of 5-HT accumulation in the brain was similar in both groups. Administration of Bay K 8644 (1 mg kg 1, i.p.) did not prevent the enhanced behaviour induced by felodipine (lOmgkg-'). 4 The 5-HT behavioural syndrome induced by injection of the 5-HTlA agonist 8-hydroxy-2{di-n-propylamino)tetralin (8-OH-DPAT) was unaltered by either acute injection of felodipine (35 mg kg 1) or administration of felodipine twice daily for 3 days. 7 Hydralazine (5mg kg 1, i.p.) induced the 5-HT behavioural syndrome in tranylcypromine pretreated rats, enhanced the tranylcypromine/L-tryptophan behavioural syndrome, inhibited 5-MeODMT-induced head twitch behaviour in mice and was not a 5-HT2 receptor antagonist. 8 These data indicate that at a high dose, Ca2+ antagonists produce complex changes in 5-HT function in rodents which are similar to those produced by lithium administration. The data with hydralazine suggest that the effects seen are not related to an action at Ca2 + channels. IntroductionRecently Boullin & Grahame-Smith (1987) In both tests the behavioural changes (head weaving, forepaw treading and flat body posture) were measured on a 0-3 score (0: absent, 1: just present; 2: present; 3: severe) as described previously (Deakin & Green, 1978;Goodwin & Green, 1985 Ltd, 1990 42 A.R. GREEN et al.However, in other experiments results are given as the combined behavioural score 40, 60 and 80min after injection and the total score of all 3 observation times. This 'shortened' observation scoring nevertheless reflected the overall pattern of behavioural change.5-HT2 receptor-mediated responses were examined following agonist administration to mice by measurement of the resultant head-twitch response as described in detail previously (Goodwin & Green, 1985). Briefly, mice were injected with 5-MeODMT (5mgkg-1, i.p.) and the total number of head twitches counted in the next 5min. Because of some variability in the response from day to day, control (vehicle injected) animals were always examined with the experimental group and to simplify presentation, results are given as the percentage inhibition of the experimental response compared to the appropriate control group. Tissue extractionIn experiments examining th...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.